Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WP 1049

Next Previous
Drug Profile

WP 1049

Alternative Names: House-dust-mite-allergy immunotherapy - Worg Pharmaceuticals; WP-1049

Latest Information Update: 28 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomay
  • Developer Worg Pharmaceuticals (Hangzhou)
  • Class Allergy immunotherapies; Antiallergics; Peptide vaccines
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hypersensitivity

Highest Development Phases

  • No development reported Hypersensitivity

Most Recent Events

  • 28 Mar 2026 No recent reports of development identified for preclinical development in Allergy in China
  • 18 Feb 2022 WP 1049 is available for licensing in Europe, USA as of 18 Feb 2022. http://www.worgpharma.com/index.php?c=category&id=51
  • 18 Feb 2022 Preclinical trials in Hypersensitivity in China (unspecified route) (Worg Pharmaceuticals pipeline, February 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top